NCT04966741View on ClinicalTrials.gov

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

September 18, 2023

Study Completion Date

November 8, 2024

Conditions
Bardet-Biedl SyndromePOMC Deficiency ObesityPCSK1 Deficiency ObesityLEPR Deficiency Obesity
Interventions
DRUG

Setmelanotide

SC injection once daily.

Trial Locations (6)

10032

Columbia University Medical Center, Division of Pediatric Endocrinology, Diabetes and Metabolism, New York

28009

Hospital Infantil Niño Jesus, Madrid

54449

Marshfield Clinic Research Foundation, Marshfield

80045

Children's Hospital Colorado, Aurora

NSW 2031

Sydney Children's Hospital, Randwick

CB2 0QQ

Addenbrooke's Hospital, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY